The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

examine here the potential role of HAART in HIV prevention and the resulting eff ect this would have on the cost-eff ectiveness of the treatment. We also discuss a theoretical HAART-driven strategy to control the continued expansion of the HIV/AIDS pandemic.

[1]  A. Caliendo,et al.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA , 2000, AIDS.

[2]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[3]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[4]  G. Schoolnik,et al.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.

[5]  R Weber,et al.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.

[6]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[7]  B. Yip,et al.  Decline in deaths from AIDS due to new antiretrovirals , 1997, The Lancet.

[8]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[9]  M. Ainscow,et al.  Mapping the issues , 2002 .

[10]  D. Velasco,et al.  Prevalencia de resistencia a los fármacos antirretrovirales en pacientes españoles infectados por el VIH y sin tratamiento previo , 2005 .

[11]  D. Stram,et al.  Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. , 1997, American journal of epidemiology.

[12]  A. Lazzarin,et al.  Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. , 1994, Archives of internal medicine.

[13]  V. Robison,et al.  Male Viral Load and Heterosexual Transmission of HIV‐1 Subtype E in Northern Thailand , 2002, Journal of acquired immune deficiency syndromes.

[14]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[15]  P. Vernazza,et al.  Effect of antiviral treatment on the shedding of HIV‐1 in semen , 1997, AIDS.

[16]  S. Blower,et al.  Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1 , 2007, Annals of Internal Medicine.

[17]  Deenan Pillay,et al.  Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe , 2004, Antiviral therapy.

[18]  Jeffrey N. Martin,et al.  Decline in HIV infectivity following the introduction of highly active antiretroviral therapy , 2003, AIDS.

[19]  HOMAS,et al.  VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 , 2000 .

[20]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[21]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[22]  H. Markel.  The search for effective HIV vaccines. , 2005, The New England journal of medicine.

[23]  C. Connolly,et al.  Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa. , 1999, AIDS.

[24]  S. Kippax,et al.  Modelling the effect of combination antiretroviral treatments on HIV incidence , 2001, AIDS.

[25]  A. Harries,et al.  Preventing tuberculosis among health workers in Malawi. , 2002, Bulletin of the World Health Organization.

[26]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[27]  G J Churchyard,et al.  Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[29]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[30]  B. Yip,et al.  Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy , 1998, AIDS.

[31]  J. Curran,et al.  The incidence rate of acquired immunodeficiency syndrome in selected populations. , 1985, JAMA.

[32]  P. Harrigan,et al.  When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. , 2005, The Lancet. Infectious diseases.

[33]  J. Castilla,et al.  Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual Transmission of HIV , 2005, Journal of acquired immune deficiency syndromes.

[34]  Douglas D. Richman,et al.  Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .

[35]  Forbes Cd,et al.  Letter: Haemophilia carriers. , 1974 .

[36]  P. Harrigan,et al.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.

[37]  Brian G. Williams,et al.  Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS , 2003, Science.

[38]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[39]  M. Diomande,et al.  The mortality and pathology of HIV infection in a West African city , 1993, AIDS.

[40]  Kiersten B. Johnson,et al.  Dimensions of the emerging orphan crisis in sub-Saharan Africa. , 2003, Social science & medicine.

[41]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[42]  D. Fuchs,et al.  Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults , 2001, AIDS.

[43]  R S Hayward,et al.  Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. , 1995, JAMA.

[44]  S. Twu,et al.  Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. , 2004, The Journal of infectious diseases.

[45]  R. Pomerantz.  Residual HIV-1 disease in the era of highly active antiretroviral therapy. , 1999, The New England journal of medicine.

[46]  A. Harries.  Predicting the failure of 3 by 5 , 2005, The Lancet.

[47]  G. Rutherford,et al.  Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda , 2006, AIDS.

[48]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[49]  J. M. Cohen,et al.  Mexico City : México , 1965 .

[50]  J. Parry,et al.  Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application , 2007, AIDS.

[51]  H. Gayle.  Expanding access to HIV prevention , 2006, AIDS research and therapy.

[52]  M. Wainberg,et al.  Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal , 2004, AIDS.

[53]  P. Vernazza,et al.  Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  P. Narciso,et al.  Risk Factors for Tuberculosis in HIV-lnfected Persons: A Prospective Cohort Study , 1995 .

[55]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[56]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[57]  D. Richman,et al.  Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. , 2005, AIDS research and human retroviruses.

[58]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[59]  M. Uplekar,et al.  WHO's new Stop TB Strategy , 2006, The Lancet.

[60]  P. Vernazza,et al.  Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV , 2000, AIDS.

[61]  M. Fowler,et al.  Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. , 2000, JAMA.

[62]  J. Zeh,et al.  Virologic characteristics of subclinical and symptomatic genital herpes infections. , 1995, The New England journal of medicine.

[63]  E. Hudes,et al.  Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. , 1992, BMJ.

[64]  R. Brunham,et al.  FEMALE TO MALE TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1: RISK FACTORS FOR SEROCONVERSION IN MEN , 1989, The Lancet.

[65]  P. Lobue,et al.  Use of isoniazid for latent tuberculosis infection in a public health clinic. , 2003, American journal of respiratory and critical care medicine.

[66]  A. Telenti,et al.  Infrequent Transmission of HIV-1 Drug-Resistant Variants , 2003, Antiviral therapy.

[67]  A. Levy,et al.  The direct costs of HIV/AIDS care. , 2006, Lancet. Infectious Diseases (Print).

[68]  S. Buskin,et al.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. , 1999, JAMA.

[69]  H. Gershengorn,et al.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.

[70]  K. D. de Cock,et al.  HIV prevention for a threatened continent: implementing positive prevention in Africa. , 2006, JAMA.

[71]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[72]  R L Ashley,et al.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera , 1988, Journal of clinical microbiology.

[73]  G. Guyatt,et al.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.

[74]  A. Prince,et al.  HEPANOSTICON IN SCREENING FOR HBsAg , 1975, The Lancet.

[75]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[76]  O. Weislow,et al.  Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[77]  P. Harrigan,et al.  Rebound of plasma HIV viral load following prolonged suppression with combination therapy. , 1998, AIDS.

[78]  R. Wood,et al.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study , 2002, The Lancet.

[79]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[80]  R. Nandwani.  2006 United Kingdom National Guideline on the Sexual Health of People with HIV: Sexually Transmitted Infections , 2006, International journal of STD & AIDS.

[81]  A. Harries,et al.  Interim policy on collaborative TB / HIV activities. , 2004 .

[82]  Paul Farmer,et al.  Community-based approaches to HIV treatment in resource-poor settings , 2001, The Lancet.

[83]  A. Lazzarin,et al.  Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. , 1994 .

[84]  K. Gelmon,et al.  HIV-1 and the aetiology of AIDS , 1993, The Lancet.

[85]  R D Moore,et al.  Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. , 2000, JAMA.

[86]  J. Chmiel,et al.  RISK FACTORS FOR SEROCONVERSION TO HUMAN IMMUNODEFICIENCY VIRUS AMONG MALE HOMOSEXUALS Results from the Multicenter AIDS Cohort Study , 1987, The Lancet.

[87]  J. Montaner,et al.  HIV treatment, injection drug use, and illicit drug policies , 2007, The Lancet.

[88]  R. Hogg,et al.  Time to act: global apathy towards HIV/AIDS is a crime against humanity , 2002, The Lancet.

[89]  R. Hogg,et al.  Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[90]  R. Steketee,et al.  HIV in the United States at the turn of the century: an epidemic in transition. , 2001, American journal of public health.

[91]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[92]  N. Letvin,et al.  The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes , 2004 .

[93]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. , 1996, JAMA.

[94]  J. Morris,et al.  Cholera among refugees in Rangsit, Thailand. , 1982, The Journal of infectious diseases.

[95]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[96]  L. Kingsley,et al.  Heterosexual HIV-1 transmission and viral load in hemophilic patients. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[97]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[98]  G. Colfax,et al.  Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. , 2005, AIDS patient care and STDs.

[99]  L. Kingsley,et al.  High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors , 1997, Journal of virology.

[100]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[101]  V. Robison,et al.  Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. , 2002 .

[102]  L. Myer,et al.  Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. , 2007, American journal of respiratory and critical care medicine.

[103]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[104]  L. Harrison,et al.  Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil , 2001, AIDS.

[105]  L. Mofenson,et al.  International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. , 2007, American journal of obstetrics and gynecology.

[106]  R. Hogg,et al.  Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. , 2002, AIDS.

[107]  J. Overbaugh,et al.  Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding , 2007, AIDS.

[108]  J A Hanley,et al.  If nothing goes wrong, is everything all right? Interpreting zero numerators. , 1983, JAMA.